Drugs / Capcecitabine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06093425 Comparator | Jun 2027 → Oct 2029 expected | gastric cancer, gastroesophageal cancer | Transcenta Therapeutics (Hangzhou) Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Capcecitabine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06093425 ↗ |